News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Tirzepatide delivers real-world benefits, safety in T2D patients in India
08 Jan 2026
byStephen Padilla
A real-world assessment of tirzepatide in Indian clinical practice has shown significant glycaemic and weight benefits in adults with type 2 diabetes (T2D). The medication is also well tolerated, with manageable gastrointestinal side effects, and highly accepted by patients.
08 Jan 2026

Long-term anti-TNF use works wonders in moderate to severe IBD
07 Jan 2026
byStephen Padilla
The use of antitumour necrosis factor (anti-TNF) agents for at least 60 months is not only safe but also effective in the treatment of moderate to severe inflammatory bowel disease (IBD), according to a study presented at AIBD 2025.
07 Jan 2026






